Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)

Mirco Lysek profile picture
Mirco Lysek


  • Fresenius Medical Care has been a long-term laggard in its industry, losing over 70% in the past 5 years.
  • The stock has seemingly bottomed and began to retrace on massive buy-side volume while breaking out of one of its most important short-term resistance.
  • In this technical article, I show important price levels and metrics that could be considered by investors to gain an overview of the stock’s price action.
  • The last time the stock had such a massive sell-off was over 20 years ago, offering a unique contrarian opportunity for more risk-tolerant investors.
One not like other, Contrarian, On contrary, opposite, be against the trend and be non-conformist


Investment thesis

Fresenius Medical Care (NYSE:FMS) has recently drawn some attention as Elliott Investment Management reportedly took a stake in the company, and investors speculate on a possible strategic restructuring of the healthcare conglomerate. Despite the stock not being in

This article was written by

Mirco Lysek profile picture
Independent trader with 18+ years of experience in the equity market. Master's Degree in Management specialized in Finance and Strategy. It’s all about managing the risk: Being wrong is unavoidable, staying wrong is a choice. While I enjoy giving my opinion on long-term investment opportunities, my focus is oriented toward momentum and mid-term position trading, as I leverage my proficiency in fundamental analysis and combine selected quantitative metrics and theories in technical analysis.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in FMS over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: All of my articles are a matter of opinion and must be treated as such. All opinions and estimates reflect my best judgment on selected aspects of a potential investment in securities of the mentioned companies, as of the date of publication. Any opinions or estimates are subject to change without notice. I am not acting in an investment adviser capacity, and this article is not financial advice. I invite every investor to do their research and due diligence before making any investment decisions. I take no responsibility for your investment decisions but wish you great success.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.